Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Isotechnika receives clearance to initiate phase I trial of TAFA-93 in Canada

May 21, 2004

Largest-ever trial begins to evaluate efficacy and safety of IGIV for CIDP

May 20, 2004

3M scientists develop immune response modifiers for use in viral infections and cancer

May 14, 2004

CTA submitted for Canadian phase I trials of TAFA-93

May 12, 2004

Biovitrum and Symphogen enter recombinant polyclonal antibody collaboration

May 12, 2004

NIH licenses rotavirus vaccine to BIOVIRx

May 11, 2004

New immunosuppressant agents covered by Kyorin patent

May 10, 2004

Merck describes new glucocorticoid receptor modulators and their use

May 5, 2004

Point's boroproline compound shows peptide adjuvant activity

May 3, 2004

Affimed presents anti-CD3 antibodies and their use in transplant rejection therapy

May 3, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...